Objective:
To analyze the risk of intraocular pressure (IOP) elevation and glaucoma development associated with higher-volume intravitreal therapies in treatment-naïve patients.
Key Findings:
- Mean IOP remained stable across all treatment groups and control groups over 24 months.
- No significant elevation in IOP or increased risk of glaucoma development was observed in patients receiving higher-volume injections.
- Cox proportional hazards analysis indicated no significant increase in risk of IOP elevation greater than 5 mmHg or above 25 mmHg, although PEG showed a statistically significant risk compared to controls.
Interpretation:
The study suggests that higher-volume intravitreal injections do not pose a significant risk for IOP elevation or glaucoma in treatment-naïve patients, corroborating findings from phase 3 clinical trials.
Limitations:
- The study is based on real-world data, which may not capture all variables influencing IOP and glaucoma risk, potentially affecting the findings.
- The isolated finding of a statistically significant risk for PEG compared to controls requires cautious interpretation.
Conclusion:
Real-world data supports that higher-volume intravitreal therapies do not increase the risk of glaucoma, but ongoing monitoring is necessary as new agents are introduced.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.